Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with an Overweight rating and a $606 price target, voicing confidence about Vertex’s renal franchise, implying that it might achieve significant market attention in 2026 and perhaps follow the success established by the company’s cystic fibrosis (CF) operation. The firm emphasized that Vertex’s CF therap ...